Lexaria Bioscience (NASDAQ:LEXX) Stock Rating Lowered by Wall Street Zen

Lexaria Bioscience (NASDAQ:LEXX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lexaria Bioscience in a research note on Tuesday, December 2nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Lexaria Bioscience presently has an average rating of “Hold” and an average price target of $4.00.

Lexaria Bioscience Price Performance

Shares of NASDAQ LEXX opened at $1.09 on Friday. The stock has a market capitalization of $24.23 million, a PE ratio of -1.68 and a beta of 0.63. Lexaria Bioscience has a one year low of $0.77 and a one year high of $2.54. The business’s fifty day moving average price is $1.00 and its 200-day moving average price is $0.98.

Institutional Investors Weigh In On Lexaria Bioscience

An institutional investor recently bought a new position in Lexaria Bioscience stock. Virtu Financial LLC bought a new position in Lexaria Bioscience Corp. (NASDAQ:LEXX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned about 0.13% of Lexaria Bioscience as of its most recent SEC filing. Institutional investors own 13.06% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.